Emerging Roles of Inhibitor of Differentiation-1 in Alzheimer's Disease: Cell Cycle Reentry and Beyond.

Alzheimer’s disease cell cycle reentry inhibitor of DNA-binding/differentiation proteins neurodegenerative diseases

Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
21 07 2020
Historique:
received: 09 06 2020
revised: 09 07 2020
accepted: 18 07 2020
entrez: 26 7 2020
pubmed: 28 7 2020
medline: 6 3 2021
Statut: epublish

Résumé

Inhibitor of DNA-binding/differentiation (Id) proteins, a family of helix-loop-helix (HLH) proteins that includes four members of Id1 to Id4 in mammalian cells, are critical for regulating cell growth, differentiation, senescence, cell cycle progression, and increasing angiogenesis and vasculogenesis, as well as accelerating the ability of cell migration. Alzheimer's disease (AD), the most common neurodegenerative disease in the adult population, manifests the signs of cognitive decline, behavioral changes, and functional impairment. The underlying mechanisms for AD are not well-clarified yet, but the aggregation of amyloid-beta peptides (Aβs), the major components in the senile plaques observed in AD brains, contributes significantly to the disease progression. Emerging evidence reveals that aberrant cell cycle reentry may play a central role in Aβ-induced neuronal demise. Recently, we have shown that several signaling mediators, including Id1, hypoxia-inducible factor-1 (HIF-1), cyclin-dependent kinases-5 (CDK5), and sonic hedgehog (Shh), may contribute to Aβ-induced cell cycle reentry in postmitotic neurons; furthermore, Id1 and CDK5/p25 mutually antagonize the expression/activity of each other. Therefore, Id proteins may potentially have clinical applications in AD. In this review article, we introduce the underlying mechanisms for cell cycle dysregulation in AD and present some examples, including our own studies, to show different aspects of Id1 in terms of cell cycle reentry and other signaling that may be crucial to alter the neuronal fates in this devastating neurodegenerative disease. A thorough understanding of the underlying mechanisms may provide a rationale to make an earlier intervention before the occurrence of cell cycle reentry and subsequent apoptosis in the fully differentiated neurons during the progression of AD or other neurodegenerative diseases.

Identifiants

pubmed: 32708313
pii: cells9071746
doi: 10.3390/cells9071746
pmc: PMC7409121
pii:
doi:

Substances chimiques

Inhibitor of Differentiation Protein 1 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

J Neuroendocrinol. 2002 Feb;14(2):101-8
pubmed: 11849369
Med Hypotheses. 2004;63(1):8-20
pubmed: 15193340
Neurology. 2020 Jan 28;94(4):e397-e406
pubmed: 31888974
Semin Cell Dev Biol. 2014 Sep;33:105-11
pubmed: 24862855
Prog Cell Cycle Res. 2003;5:31-41
pubmed: 14593698
Mol Neurobiol. 2019 Jan;56(1):465-489
pubmed: 29721855
Genomics. 1995 May 1;27(1):200-3
pubmed: 7665172
J Neurosci Res. 2008 Mar;86(4):845-60
pubmed: 17969100
Nat Rev Cancer. 2005 Aug;5(8):603-14
pubmed: 16034366
Bioessays. 2012 Oct;34(10):849-56
pubmed: 22903465
J Neurosci. 2002 Sep 15;22(18):7879-91
pubmed: 12223541
J Neurosci. 2008 Oct 22;28(43):10786-93
pubmed: 18945886
Neuropathol Appl Neurobiol. 2010 Apr;36(2):157-63
pubmed: 20059701
Pharmacol Ther. 2006 Jul;111(1):99-113
pubmed: 16274748
Neuroreport. 2001 Aug 8;12(11):2461-5
pubmed: 11496130
Eur J Biochem. 2001 Mar;268(6):1528-33
pubmed: 11248669
Proc Natl Acad Sci U S A. 1993 May 1;90(9):4304-8
pubmed: 8387214
Ann N Y Acad Sci. 2005 May;1042:357-64
pubmed: 15965081
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
Brain Res Bull. 2017 Jun;132:28-38
pubmed: 28526617
EMBO Mol Med. 2016 Jun 01;8(6):595-608
pubmed: 27025652
Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
pubmed: 7539918
FASEB J. 2019 Apr;33(4):5257-5267
pubmed: 30668139
Behav Brain Res. 2015 Oct 1;292:528-36
pubmed: 26187693
Neuron. 2003 Jul 3;39(1):43-56
pubmed: 12848931
Biochem Pharmacol. 2020 Jan;171:113720
pubmed: 31751533
Cell Cycle. 2015;14(5):712-20
pubmed: 25590687
Rev Neurosci. 2017 Nov 27;28(8):825-843
pubmed: 28704198
Brain Res. 2011 Mar 24;1381:1-10
pubmed: 20977891
Neurosurgery. 2011 May;68(5):1342-53; discussion 1353
pubmed: 21307796
Nat Neurosci. 2003 Jan;6(1):21-7
pubmed: 12469128
Neurotox Res. 2012 Oct;22(3):195-207
pubmed: 21965004
Oncogene. 2001 Dec 20;20(58):8317-25
pubmed: 11840324
Curr Top Med Chem. 2006;6(6):597-608
pubmed: 16712494
Neurochem Int. 2009 Feb;54(2):84-8
pubmed: 19114068
Clin Exp Pharmacol Physiol. 2017 Mar;44(3):327-334
pubmed: 28004401
Dev Cell. 2015 Nov 9;35(3):269-80
pubmed: 26555048
Cell Cycle. 2009 Jan 1;8(1):97-104
pubmed: 19158499
J Biol Chem. 1995 Jan 20;270(3):1230-7
pubmed: 7836384
J Alzheimers Dis. 2015;44(2):613-24
pubmed: 25318543
Cell Cycle. 2008 Mar 1;7(5):637-46
pubmed: 18239458
Brain Res Mol Brain Res. 1997 Jun;46(1-2):136-42
pubmed: 9191087
Neurosci Lett. 2013 Oct 25;554:88-93
pubmed: 23994058
Nature. 2000 May 18;405(6784):360-4
pubmed: 10830966
J Neurosci. 2016 Nov 2;36(44):11283-11294
pubmed: 27807169
Ann N Y Acad Sci. 2009 Jul;1170:674-9
pubmed: 19686210
Stem Cells Dev. 2013 Mar 15;22(6):913-27
pubmed: 23199293
J Neurosci. 2003 Apr 1;23(7):2557-63
pubmed: 12684440
Chem Rev. 2012 Oct 10;112(10):5147-92
pubmed: 22813427
Glia. 1998 Dec;24(4):372-81
pubmed: 9814817
Prog Neurobiol. 2009 Sep;89(1):1-17
pubmed: 19619927
Cell Cycle. 2015;14(13):2022-32
pubmed: 26038996
Curr Pharm Des. 2016;22(5):527-34
pubmed: 26601962
Anat Rec (Hoboken). 2009 Dec;292(12):1953-61
pubmed: 19943348
J Biol Chem. 2014 Apr 11;289(15):10812-22
pubmed: 24567336
Glia. 1999 Apr;26(2):139-52
pubmed: 10384879
Front Oncol. 2016 May 02;6:113
pubmed: 27200299
Trends Cell Biol. 2013 Jul;23(7):345-56
pubmed: 23566594
Aging Cell. 2010 Feb;9(1):64-77
pubmed: 19895631
Biochem Biophys Res Commun. 2005 Sep 23;335(2):458-68
pubmed: 16083855
Biochim Biophys Acta Mol Basis Dis. 2017 Jan;1863(1):324-336
pubmed: 27639832
Nat Neurosci. 2010 Jul;13(7):812-8
pubmed: 20581818
Development. 2013 Aug;140(16):3303-9
pubmed: 23900539
Nat Rev Neurosci. 2007 May;8(5):368-78
pubmed: 17453017
Curr Med Chem. 2011;18(28):4335-43
pubmed: 21861815
J Neurosci Res. 2000 Jul 15;61(2):128-33
pubmed: 10878584
J Cancer. 2010 Jun 01;1:1-5
pubmed: 20842217
J Cell Sci. 2012 Nov 1;125(Pt 21):5124-37
pubmed: 22899714
N Engl J Med. 2011 Aug 11;365(6):537-47
pubmed: 21830968
Nature. 1999 Dec 9;402(6762):615-22
pubmed: 10604467
Curr Top Dev Biol. 2014;110:189-216
pubmed: 25248477
Mol Neurobiol. 2016 Sep;53(7):4328-42
pubmed: 26227906
Dev Dyn. 1996 Nov;207(3):235-52
pubmed: 8922523
Methods Mol Biol. 2017;1524:331-349
pubmed: 27815913
Nucleic Acids Res. 1994 Mar 11;22(5):749-55
pubmed: 8139914
Biochim Biophys Acta Mol Cell Res. 2020 Apr;1867(4):118628
pubmed: 31884068
Cell Growth Differ. 1995 Jul;6(7):837-43
pubmed: 7547505
Stem Cells. 2011 Jul;29(7):1090-101
pubmed: 21608079
Biochem Biophys Res Commun. 2017 Apr 29;486(2):564-570
pubmed: 28327358
J Neurosci. 2013 Jan 30;33(5):1915-26
pubmed: 23365231
Int J Cancer. 2012 Oct 1;131(7):E1078-87
pubmed: 22514120
Nucleic Acids Res. 2011 Jun;39(11):4553-63
pubmed: 21335608
J Neurochem. 2002 Mar;80(5):755-62
pubmed: 11948238
J Clin Invest. 2013 Sep;123(9):3664-71
pubmed: 23999440
Proc Natl Acad Sci U S A. 1991 Mar 1;88(5):1815-9
pubmed: 2000388
Cell Rep. 2016 Aug 9;16(6):1629-1641
pubmed: 27477274
Genes Dev. 2008 Aug 1;22(15):2028-33
pubmed: 18676808
Nature. 1999 Oct 14;401(6754):670-7
pubmed: 10537105
Cell. 1990 Apr 6;61(1):49-59
pubmed: 2156629
Nat Rev Mol Cell Biol. 2005 Jan;6(1):9-20
pubmed: 15688063
Mol Cell Biol. 1991 Nov;11(11):5603-11
pubmed: 1922066
Br J Pharmacol. 2004 Mar;141(6):988-96
pubmed: 14980978
J Cell Physiol. 2011 Jul;226(7):1763-70
pubmed: 21506108
Exp Neurol. 2014 Mar;253:63-71
pubmed: 24368194
Int J Mol Sci. 2018 Aug 16;19(8):
pubmed: 30115884
Annu Rev Neurosci. 2011;34:185-204
pubmed: 21456963
Exp Cell Res. 1999 Mar 15;247(2):347-55
pubmed: 10066362
Mol Neurobiol. 2016 Mar;53(2):793-809
pubmed: 25502463
Trends Neurosci. 2016 Dec;39(12):840-850
pubmed: 27865563
Oncogene. 2010 Jul 1;29(26):3793-802
pubmed: 20453881
Cell Stem Cell. 2009 Nov 6;5(5):515-26
pubmed: 19896442
Stem Cells Dev. 2010 Jun;19(6):831-41
pubmed: 19757990

Auteurs

Shang-Der Chen (SD)

Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833401, Taiwan.
Institute for Translation Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833401, Taiwan.

Jenq-Lin Yang (JL)

Institute for Translation Research in Biomedicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833401, Taiwan.

Yi-Chun Lin (YC)

Department of Neurology, Taipei City Hospital, Taipei City 106243, Taiwan.

A-Ching Chao (AC)

Department of Neurology, College of Medicine, Kaohsiung Medical University, Kaohsiung City 807378, Taiwan.
Department of Neurology, Kaohsiung Medical University Hospital, Kaohsiung City 807377, Taiwan.

Ding-I Yang (DI)

Institute of Brain Science, National Yang-Ming University, Taipei City 112304, Taiwan.
Brain Research Center, National Yang-Ming University, Taipei City 112304, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH